Honors & Awards

  • A*STAR National Science Scholarship (PhD), Agency for Science, Technology & Research (A*STAR) (June 2019)
  • EMBO/SCSS Conference Travel Award, European Molecular Biology Organization, Singapore Stem Cell Society Singapore (September 2018)
  • Development, Regeneration and Stem Cell Biology Honours Class Prize, The University of Edinburgh (November 2017)
  • Duke of Edinburgh's International Award, National Youth Achievement Award Council (October 2014)
  • A*STAR National Science Scholarship (BS), Agency for Science, Technology & Research (A*STAR) (July 2013)
  • Academic Award for Outstanding Performance Academic Year 2012/2013, Singapore Polytechnic (April 2013)
  • A*STAR Science Award (Polytechnic), Agency for Science, Technology & Research (A*STAR) (November 2012)

Membership Organizations

Education & Certifications

  • BSc (Hons) 1st Class, The University of Edinburgh, Development, Regeneration, and Stem Cell Biology (2018)
  • Diploma (Distinction), Singapore Polytechnic, Biotechnology (2013)

All Publications

  • Large-Scale Production of Wholly-Cellular Bioinks via the Optimization of Human Induced Pluripotent Stem Cell Aggregate Culture in Automated Bioreactors. Advanced healthcare materials Ho, D. L., Lee, S., Du, J., Weiss, J. D., Tam, T., Sinha, S., Klinger, D., Devine, S., Hamfeldt, A., Leng, H. T., Herrmann, J. E., He, M., Fradkin, L. G., Tan, T. K., Traul, D., Vicard, Q., Katikireddy, K., Skylar-Scott, M. A. 2022: e2201138


    Combining the sustainable culture of billions of human cells and the bioprinting of wholly-cellular bioinks offers a pathway towards organ-scale tissue engineering. Traditional 2D culture methods are not inherently scalable due to cost, space, and handling constraints. Here, we optimize the suspension culture of human induced pluripotent stem cell-derived aggregates using an automated 250 mL stirred tank bioreactor system. Cell yield, aggregate morphology, and pluripotency marker expression are maintained over three serial passages in two distinct cell lines. Furthermore, we demonstrate that the same optimized parameters can be scaled to an automated 1 L stirred tank bioreactor system. Our 4-day culture resulted in a 16.6- to 20.4-fold expansion of cells, we generate approximately 4 billion cells per vessel, while maintaining > 94% expression of pluripotency markers. The pluripotent aggregates can be subsequently differentiated into derivatives of the three germ layers, including cardiac aggregates, and vascular, cortical and intestinal organoids. Finally, the aggregates are compacted into a wholly-cellular bioink for rheological characterization and 3D bioprinting. The printed hAs are subsequently differentiated into neuronal and vascular tissue. This work demonstrates an optimized suspension culture-to-3D bioprinting pipeline that enables a sustainable approach to billion cell-scale organ engineering. This article is protected by copyright. All rights reserved.

    View details for DOI 10.1002/adhm.202201138

    View details for PubMedID 36314397

  • Human Finger-Prick Induced Pluripotent Stem Cells Facilitate the Development of Stem Cell Banking STEM CELLS TRANSLATIONAL MEDICINE Tan, H., Toh, C., Ma, D., Yang, B., Liu, T., Lu, J., Wong, C., Tan, T., Li, H., Syn, C., Tan, E., Lim, B., Lim, Y., Cook, S. A., Loh, Y. 2014; 3 (5): 586–98


    Induced pluripotent stem cells (iPSCs) derived from somatic cells of patients can be a good model for studying human diseases and for future therapeutic regenerative medicine. Current initiatives to establish human iPSC (hiPSC) banking face challenges in recruiting large numbers of donors with diverse diseased, genetic, and phenotypic representations. In this study, we describe the efficient derivation of transgene-free hiPSCs from human finger-prick blood. Finger-prick sample collection can be performed on a "do-it-yourself" basis by donors and sent to the hiPSC facility for reprogramming. We show that single-drop volumes of finger-prick samples are sufficient for performing cellular reprogramming, DNA sequencing, and blood serotyping in parallel. Our novel strategy has the potential to facilitate the development of large-scale hiPSC banking worldwide.

    View details for DOI 10.5966/sctm.2013-0195

    View details for Web of Science ID 000335939000015

    View details for PubMedID 24646489

    View details for PubMedCentralID PMC4006490